ibodutant

Also Known As:

benzo(b)thiophene-2-carboxamide, 6-methyl-N-(1-((((1R)-2- oxo-1-(phenylmethyl)-2-(((1-((tetrahydro-2H-pyran-4- yl)methyl)-4- piperidinyl)methyl)amino)ethyl)amino)carbonyl)cyclopentyl)-

Networked: 5 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - Dipeptides: 945
      - ibodutant: 5
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiophenes: 257
    - ibodutant: 5
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Thiophenes: 257
    - ibodutant: 5

Experts

1.	Maggi, C A: 2 articles (01/2017 - 04/2016)
2.	Drimousis, Stelina: 1 article (10/2020)
3.	Liu, Lu: 1 article (10/2020)
4.	Markus, Irit: 1 article (10/2020)
5.	Murphy, Tim V: 1 article (10/2020)
6.	Perera, D Shevy: 1 article (10/2020)
7.	Phan-Thien, Kim-Chi: 1 article (10/2020)
8.	Zhang, Li: 1 article (10/2020)
9.	Fichna, J: 1 article (02/2019)
10.	Malkiewicz, A: 1 article (02/2019)

Related Diseases

1.	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 04/01/2016 - "The tachykinin NK2 receptor antagonist ibodutant is under Phase III clinical investigation to treat female patients with irritable bowel syndrome. " 10/01/2020 - "In patients with diarrhea-predominant irritable bowel syndrome, the NK2 receptor antagonist ibodutant had a greater therapeutic effect in females than males. " 05/01/2009 - "Ibodutant (MEN15596, [1-(2-phenyl-1R-[[1-(tetrahydropyran-4-ylmethyl)-piperidin-4-ylmethyl]-carbamoyl]-ethylcarbamoyl)-cyclopentyl]-amide) is a tachykinin NK(2) receptor (NK(2)R) antagonist currently under phase II clinical trials for irritable bowel syndrome. "
2.	Diarrhea 02/01/2019 - "Ibodutant is a novel drug with an interesting pharmacological profile, which exerted efficacy in women with diarrhea-predominant IBS (IBS-D) in phase II clinical trials. " 10/01/2020 - "In patients with diarrhea-predominant irritable bowel syndrome, the NK2 receptor antagonist ibodutant had a greater therapeutic effect in females than males. "
3.	Abdominal Pain (Pain, Abdominal) 01/01/2017 - "The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS."
4.	Hypersensitivity (Allergy) 04/01/2016 - "Ibodutant prevented abdominal nociception in a model of visceral hypersensitivity in guinea pigs with a greater efficacy in females than in males. " 04/01/2016 - "After TNBS-induced colitis, ibodutant prevented the increased visceral hypersensitivity to CRD in females, at lower doses than in males. "
5.	Colitis 04/01/2016 - "After TNBS-induced colitis, ibodutant prevented the increased visceral hypersensitivity to CRD in females, at lower doses than in males. "

Related Drugs and Biologics

1.	Neurokinin-2 Receptors (Neurokinin 2 Receptor)
2.	Tachykinins
3.	Amides
4.	6-methylbenzo(b)thiophene-2-carboxylic acid (1- (2- phenyl- ((1- (tetrahydropyran- 4- ylmethyl)piperidin- 4- ylmethyl)carbamoyl)ethylcarbamoyl)cyclophenyl)amide
5.	NK 2 (NK-2)
6.	Therapeutic Uses